Zelnorm

Drug for Irritable Bowel Syndrome, Withdrawn

The FDA announced that Novartis Pharmaceuticals has agreed to stop marketing Zelnorm (tegaserod), used to treat irritable bowel syndrome, after a recent safety analysis found an increased risk for serious cardiovascular events.

Zelnorm was approved for short-term treatment of women with irritable bowel syndrome whose primary symptom is constipation and for men and women younger than 65 with chronic constipation.

An analysis of 29 placebo-controlled clinical trials comprising over 18,000 patients conducted by Novartis found 0.1% of patients taking Zelnorm showed evidence of a serious cardiovascular event, compared with 0.01% taking a placebo. The FDA concluded that, for most patients, the benefits of Zelnorm no longer outweigh the risks. The agency is working with the manufacturer to keep the drug available for those who have no other treatment options.

Get Help

Were you injured by a defective drug or supplement? If so, please save the product and instructions for the product. Also, if you have the box the product came in that would be helpful. All of this information may be vital to proving your case. Contact us for a free evaluation of your claim. 1-866-250-1786, local 651-641-1500.

Disclaimer: Always seek the advice of a qualified legal professional regarding any legal issues you may have. You should not disregard professional advice or refrain from seeking professional advice because of anything contained in this Web site. The information contained herein is general and educational in nature and may not be current or updated. Because each case is different and each legal analysis is customized for individual clients, the information contained in this Web site should never be used to determine your legal rights.

Back to Pharmaceutical Drug Injury